跳至主要内容
临床试验/NCT03061110
NCT03061110撤回1 期

Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System® ("Icellator") Autologous Adipose Stromal Vascular Fraction Cells as a Treatment for Post-Irradiated Induced Xerostomia in Head and Neck Cancer Patients

Midwestern Regional Medical Center1 个研究点 分布在 1 个国家开始时间: 2018年11月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
撤回
发起方
试验地点
1
主要终点
Acute Safety Profile (Reported Adverse Events graded according to CTCAE guidelines)

研究概览

简要总结

Prospective, single center, double armed, randomized treatment with observation only (standard of care) control group. Subjects receiving study treatment will have 6 months of study follow-up. Stromal vascular fraction (SVF), an adipose-derived tissue preparation, will be injected into salivary glands to determine safety and efficacy to restore saliva production in head and neck cancer patients with chronic xerostomia resulting from radiation therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male and Female subjects are both eligible
  • •Subjects must be 21 years of age or older
  • •History of treated Head and Neck Cancer, no evidence of active cancer at the time of the study
  • •Original tumor not located adjacent to the parotid or sub-mandibular glands
  • •Diagnosis of radiation-induced xerostomia
  • •study is fully explained
  • •Females of child bearing potential agree to use acceptable methods of contraception through 6 month study follow-up.
  • •No current malignancy or history of previous malignancy within the last five years, other than the head and neck cancer, with the exception of adequately treated non-abdominal, non-melanoma cutaneous carcinoma (basal cell or squamous cell carcinoma of the skin)
  • •Willing to undergo a minor surgical procedure (small-volume liposuction, totaling approximately 60-120cc) and a single treatment of an injection of approximately 30ml of autologous Stromal Vascular Fraction taking approximately 10 minutes
  • •Abdominal area amenable to liposuction of at least 60-120cc of adipose tissue based on Investigator(s) examination
  • •Willing to be available for all baseline, treatment and follow-up examinations required by protocol
  • •Willing to forego participation in any other study throughout the duration of this study unless receiving prior approval by Investigator

排除标准

  • •Patients taking immunosuppressive therapy in the prior 3 months
  • •Autoimmune disorders
  • •Patients who are pregnant or currently breast-feeding children
  • •Patients participating in a study of an experimental drug or medical device within 60 days of study entry
  • •Uncontrolled hypertension
  • •Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening
  • •Hemoglobin A1c > 8% within 8 weeks prior to study treatment
  • •Current use of steroids or immunosuppressant therapies
  • •Any other condition, which, in the opinion of the Investigator, would contraindicate treatment, affect compliance, interfere with study evaluations, limit study participation, or confound the interpretation of study results
  • •History of Sjogren's Syndrome or related autoimmune disease.
  • •Taking medication for which xerostomia is a known major side effect

研究组 & 干预措施

Usual Care

Active Comparator

Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.

干预措施: Usual Care (Other)

Stromal Vascular Fraction

Experimental

Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).

干预措施: Stromal Vascular Fraction (Biological)

结局指标

主要结局

Acute Safety Profile (Reported Adverse Events graded according to CTCAE guidelines)

时间窗: 72 hours

Reported Adverse Events graded according to CTCAE guidelines will be recorded starting at or after the time of injection and at or before 72 hours post injection.

次要结局

  • Chronic Safety Profile (Reported Adverse Events graded according to Common Terminology Criteria for Adverse Events (CTCAE) guidelines)(Months 3, 6 and 12 after Day 0 (date of injection))
  • Unstimulated Saliva Production(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • Stimulated Saliva Production(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In the open air)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In the open air in case of wind and cold)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In air-conditioned spaces)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially dry mouth during daytime)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially dry mouth at nighttime)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Always dry mouth night and day)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially bother of the dry mouth during meals)(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire- "How often do you wake up at night because of a dry mouth?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "How would you describe the quality of your saliva?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire- "How severe is your dry mouth problem?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have difficulties with speech because of the dry mouth?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to sip water to facilitate speech?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Is swallowing changed because of the dry mouth problem?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Has the dry mouth a negative influence on chewing?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to sip water to facilitate eating?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did you change your feeding habits?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have painful, dry, or crusted lips?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to carry a bottle of fluid with you when leaving home?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have a sore or painful mouth?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did your taste change?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you often have an infected oral mucosa or irritated gums?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did your teeth deteriorate after radiation therapy?"(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Rotterdam Hospital Xerostomia Questionnaire - Overall Xerostomia Index(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Physical Functioning(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Pain/Discomfort(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Personal/Psychological Functioning(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Social Functioning(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)
  • Late Effects Normal Tissue-Subjective Objective Management Analytica (LENT-SOMA) survey(Assessed at Baseline and 3 months, 6 months and 12 months after Baseline)

研究者

发起方
Midwestern Regional Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Stephen Ray, MD

Surgeon

Midwestern Regional Medical Center

研究点 (1)

Loading locations...

相似试验